These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 28752287

  • 21. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
    Kato S, Ando M, Mizukoshi T, Nagata T, Katsuno T, Kosugi T, Tsuboi N, Maruyama S.
    Nagoya J Med Sci; 2016 May; 78(2):135-42. PubMed ID: 27303100
    [Abstract] [Full Text] [Related]

  • 22. Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.
    Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, Konta T, Shoji T, Mima A, Mukoyama M, Saito Y.
    Clin Exp Nephrol; 2024 Aug; 28(8):764-772. PubMed ID: 38530491
    [Abstract] [Full Text] [Related]

  • 23. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M, Cicero AFG, Borghi C.
    Curr Hypertens Rep; 2017 Oct 25; 19(12):95. PubMed ID: 29071435
    [Abstract] [Full Text] [Related]

  • 24. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
    Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S.
    Ren Fail; 2014 Mar 25; 36(2):225-31. PubMed ID: 24152124
    [Abstract] [Full Text] [Related]

  • 25. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
    Nagaoka Y, Tanaka Y, Yoshimoto H, Suzuki R, Ryu K, Ueda M, Akiyama M, Nagai M, Miyaoka Y, Kanda E, Iwai S, Nagaoka M, Kanno Y.
    Hemodial Int; 2018 Jul 25; 22(3):388-393. PubMed ID: 29227568
    [Abstract] [Full Text] [Related]

  • 26. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP, Leung KT, Tong MK, Kwan TH.
    Am J Kidney Dis; 2006 Jan 25; 47(1):51-9. PubMed ID: 16377385
    [Abstract] [Full Text] [Related]

  • 27. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K, Tana T, Higa A, Yamazato M, Ishida A, Nagahama K, Sakima A, Iseki K, Ohya Y.
    Hypertens Res; 2016 Aug 25; 39(8):593-7. PubMed ID: 27075830
    [Abstract] [Full Text] [Related]

  • 28. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
    Okui D, Sasaki T, Fushimi M, Ohashi T.
    Clin Exp Nephrol; 2020 Mar 25; 24(Suppl 1):92-102. PubMed ID: 31734820
    [Abstract] [Full Text] [Related]

  • 29. Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
    Wakita M, Asai K, Kubota Y, Koen M, Shimizu W.
    J Nippon Med Sch; 2021 Nov 17; 88(5):423-431. PubMed ID: 33455978
    [Abstract] [Full Text] [Related]

  • 30. Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.
    Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI.
    Pediatr Nephrol; 2017 Sep 17; 32(9):1565-1573. PubMed ID: 28382567
    [Abstract] [Full Text] [Related]

  • 31. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F, Assadi F.
    Pediatr Nephrol; 2018 Aug 17; 33(8):1405-1409. PubMed ID: 29549464
    [Abstract] [Full Text] [Related]

  • 32. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
    Mitsuboshi S, Yamada H, Nagai K, Okajima H.
    Biol Pharm Bull; 2017 Aug 17; 40(9):1463-1467. PubMed ID: 28867729
    [Abstract] [Full Text] [Related]

  • 33. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
    Sakuma M, Toyoda S, Arikawa T, Koyabu Y, Kato T, Adachi T, Suwa H, Narita JI, Anraku K, Ishimura K, Yamauchi F, Sato Y, Inoue T.
    PLoS One; 2022 Aug 17; 17(1):e0261445. PubMed ID: 35077456
    [Abstract] [Full Text] [Related]

  • 34. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
    Kim Y, Shin S, Kim K, Choi S, Lee K.
    J Rheumatol; 2015 Nov 17; 42(11):2143-8. PubMed ID: 26428209
    [Abstract] [Full Text] [Related]

  • 35. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ.
    Am J Kidney Dis; 2015 Dec 17; 66(6):984-92. PubMed ID: 26209544
    [Abstract] [Full Text] [Related]

  • 36. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.
    Kawamorita Y, Shiraishi T, Tamura Y, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Nakagawa T, Uchida S.
    Physiol Rep; 2017 Aug 17; 5(15):. PubMed ID: 28774949
    [Abstract] [Full Text] [Related]

  • 37. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW, Lee KH.
    Int Urol Nephrol; 2019 Mar 17; 51(3):467-473. PubMed ID: 30604229
    [Abstract] [Full Text] [Related]

  • 38. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
    Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, Sakamoto R.
    Eur J Pharmacol; 2016 Jun 05; 780():224-31. PubMed ID: 27038523
    [Abstract] [Full Text] [Related]

  • 39. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial.
    Mizukoshi T, Kato S, Ando M, Sobajima H, Ohashi N, Naruse T, Saka Y, Shimizu H, Nagata T, Maruyama S.
    Nephrology (Carlton); 2018 Nov 05; 23(11):1023-1030. PubMed ID: 28990729
    [Abstract] [Full Text] [Related]

  • 40. Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
    Yamaguchi A, Harada M, Yamada Y, Hashimoto K, Kamijo Y.
    BMC Nephrol; 2017 May 18; 18(1):162. PubMed ID: 28521802
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.